Table 2 Metastasis free survival—comparison of the stratified hazard ratios
Metastatic progression | ||||
|---|---|---|---|---|
TMA population | mRNA population | |||
Subgroups | Metaprog/N | HR (95% CI) (2 vs 0/1) | Metaprog/N | HR (95% CI) (<=8 vs >8) |
Overall | 13/79 | 1.25 (0.38–4.05) | 29/87 | 3.36 (1.43–7.92) |
Adjusted effect on age | 13/79 | 1.38 (0.42–4.51)a | 29/85 | 3.60 (1.53–8.47) |
Adjusted effect on menopause | 13/79 | 1.19 (0.37–3.88) | 29/86 | 3.24 (1.37–7.67) |
Adjusted effect on pT | 13/79 | 1.77 (0.53–5.93) | 29/86 | 3.23 (1.36–7.65) |
Adjusted effect on histological type | 13/79 | 1.05 (0.32–3.42)a | 29/86 | 2.99 (1.27–7.05) |
Adjusted effect on SBR | 13/79 | 0.96 (0.29–3.17) | 28/81 | 3.14 (1.32–7.45) |
Adjusted effect on N | 13/79 | 1.19 (0.36–3.93) | 29/87 | 2.77 (1.17–6.52) |
Adjusted effect on ER (%) | 13/79 | 0.84 (0.23–3.03) | 28/84 | 3.14 (1.32–7.47) |
Adjusted effect on PR (%) | 13/79 | 0.90 (0.26–3.14) | 29/86 | 3.23 (1.37–7.62) |
Adjusted effect on HER2 | 13/79 | 1.34 (0.40–4.48) | 21/64 | 2.26 (0.85–6.00) |
Adjusted effect on luminal A | 12/77 | 1.07 (0.30–3.83) | 21/63 | 2.64 (0.99–7.00) |
Adjusted effect on cancer subtype | 12/77 | 0.76 (0.18–3.18) | 21/63 | 2.59 (0.97–6.89) |
